Sub menu

 

 

CABOMETYX (Ipsen Pty Ltd)

Product name
CABOMETYX
Sponsor
Ipsen Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
74 working days (120)
Active ingredients
cabozantinib
Registration type
EOI
Indication
Hepatocellular Carcinoma (HCC)

CABOMETYX (film-coated tablets) is now also indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

Help us improve this page